New research indicates that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who stop conventional lifestyle plans.
Research printed in a leading medical journal shows that while overweight individuals often shed about a fifth of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such drugs must be informed of the potential of rapid rebound weight gain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight in about 18 months.
Analyzing Treatments
The research, which examined 37 of studies involving thousands of participants, contrasted the results of these new drugs with older methods.
The team point out that individuals who lose weight through dieting generally have a slower creep back—around 100 grams monthly—post-intervention.
Explaining the Fast Regain
Doctors suggest the mechanism of the injections accounts for the amplified weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Condition?
The NHS recommend the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Professionals say that, considering the high risk of weight regain, the therapy is often ongoing.
This view is reinforced by drug manufacturers, who state that the results "underscore the chronic nature of excess weight," comparing it to managing conditions like diabetes.
User Testimonies
Individuals who have discontinued the jabs explain a intense resurgence of hunger.
"It felt as if a trigger that goes on and you become ravenous," recalled an individual.
This difficulty is compounded if individuals have not established sustainable dietary or behavioural changes during therapy.
Widespread Interest
Survey data suggest that millions of adults in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is higher among females than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a magic cure and lasting health benefits relies on ongoing behavioural management.
